The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes, marking the first once-weekly basal insulin approved in the US.
|Articles|December 1, 2007
Bubble, Bubble, No Trouble Exam
Blowing bubbles is an effective way to gain a young patient's attention.
Advertisement
Blowing bubbles is an effective way to gain a young patient's attention. You can then ask the child's parent to blow the bubbles as you proceed with your examination. When the time comes to examine the lungs, ask the parent to have the child take over. It gives him or her something to focus on and typically results in a good, consistent respiratory effort.
-- Mark Shatsky, DO
Lake Oswego, Ore
Advertisement
Related to this article
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
Advertisement
Advertisement
Trending on Patient Care Online
1
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
2
Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
5